Other models show promise of combining ruxolitinib with a BCL-2 inhibitor [20, 22, 39]; venetoclax is currently in clinical trials to treat additional hematological malignancies beyond CLL, either as a monotherapy or in combination with other chemotherapeutic agents. Here, BCL2 is linked to hematologic disorder.